drugset / Trial / NCT01510704

Phase II Dose-ranging Study of APD421 in PONV

NCT01510704

Phase 2 Completed 215 enrolled Acacia Pharma Ltd
RandomizedParallel-groupQuadruple-blindPrevention

Summary

To assess the efficacy and safety of different doses of APD421 in the prevention of post-operative nausea and vomiting (PONV) in adult patients at moderate to high-risk of PONV. Patients must be undergoing elective surgery under general anaesthesia (hysterectomy (any surgical technique), cholecystectomy (any surgical technique) or "other" elective surgery scheduled to last at least one hour from induction of anaesthesia), requiring at least one overnight stay in hospital, and have at least 2 of the following risk factors for PONV: Past history of PONV and/or motion sickness; Non-smoking status; Female gender; Planned opiate use for post-operative analgesia.

Timeline

Start
2012-01
Primary completion
2012-04
Completion
2012-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Amisulpride Small molecule 1 mg Intravenous
Subject Amisulpride Small molecule 5 mg Intravenous
Subject Amisulpride Small molecule 20 mg Intravenous

Indications

No indication recorded.